IQVIA (NYSE:IQV) Stock Rating Lowered by BTIG Research

IQVIA (NYSE:IQV) was downgraded by stock analysts at BTIG Research from a “buy” rating to a “neutral” rating in a report released on Monday, MarketBeat Ratings reports.

IQV has been the topic of several other reports. Leerink Partners restated an “outperform” rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. TD Cowen decreased their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Wednesday, December 11th. JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. Finally, Bank of America reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $254.53.

IQVIA Trading Up 0.4 %

IQV opened at $200.00 on Monday. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The firm has a market cap of $36.30 billion, a PE ratio of 26.25, a price-to-earnings-growth ratio of 2.15 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The firm’s fifty day moving average is $200.31 and its two-hundred day moving average is $220.14.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. FMR LLC grew its holdings in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after buying an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Impax Asset Management Group plc lifted its position in shares of IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after purchasing an additional 157,809 shares in the last quarter. Nordea Investment Management AB grew its position in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in IQVIA by 3.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock valued at $290,545,000 after buying an additional 39,772 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.